![Vijay Reddy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Vijay Reddy formerly worked at MedImmune LLC, as Medical Director, Janssen Pharmaceuticals, Inc., as Medical Director-Oncology, the University of Central Florida, as Professor, and Actinium Pharmaceuticals, Inc., as Vice President-Clinical Development from 2018 to 2022.
Eerdere bekende functies van Vijay Reddy
| Bedrijven | Functie | Einde |
|---|---|---|
| ACTINIUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-02-2022 |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Hoofd Techniek/Wetenschap/O&O | - |
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Hoofd Techniek/Wetenschap/O&O | - |
University of Central Florida
 University of Central Florida Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
7
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
MedImmune LLC
MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Health Technology |
University of Central Florida
University of Central Florida Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Actinium Pharmaceuticals, Inc.
 Actinium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers | Health Technology |
Kies MarketScreener 
